November 5, 2007 – Boston Scientific Corp. highlighted at the American Heart Association conference its new Stentplus Patient Success Program, which provides tools designed for a cardiology team to assist drug-eluting stent patients—regardless of stent brand—to comply with dual anti-platelet therapy.

The primary goal of the program is to help improve patient adherence and patient outcomes through educational tools and assistance in identifying financial resources.

November 5, 2007 - Pinyons Medical Technology announced it received FDA clearance to market the PowrSyringe Injector, a disposable hand-held device designed to offer ergonomic and mechanical advantages to inject and aspirate fluids including use in angiography.

The Injector’s crossing handles hinge to the syringe barrel and plunger to advance the plunger into the barrel when the handles are squeezed.

The PowrSyringe is designed to bridge the gap between syringes and electronic power injectors.

November 5, 2007 - A pooled analysis of the E-SIRIUS and C-SIRIUS trials, called New SIRIUS, found that the CYPHER sirolimus-eluting coronary stent continued to provide clinical benefits with similar safety compared to a bare metal stent at five-year follow-up, according to data presented at the American Heart Association Scientific Session 2007.

November 5, 2007 - According to late-breaking clinical trial results presented at the American Heart Association’s Scientific Sessions 2007, a high-tech imaging technique might replace the more invasive standard coronary angiography as a way for doctors to look at blockages in heart arteries in some patients.

Pinyons Medical Technology offers the FDA-cleared PowrSyringe Injector, a disposable hand-held device designed to offer ergonomic and mechanical advantages to inject and aspirate fluids including use in angiography.

The Injector’s crossing handles hinge to the syringe barrel and plunger to advance the plunger into the barrel when the handles are squeezed.

November 4, 2007 – Drug-eluting stents to open blocked coronary arteries caused no more risks for death or heart attack than bare metal stents, according to a late-breaking outcomes trial presented at the American Heart Association’s Scientific Sessions 2007.

November 4, 2007 – A specific way of dosing eptifibatide appears equally effective as giving abciximab as an adjunct to primary percutaneous coronary intervention (PCI) in restoring blood flow to the heart, according to late-breaking clinical trial results announced at the American Heart Association’s Scientific Sessions 2007.

November 4, 2007 – Single photon emission computed tomography (SPECT) can identify which patients will benefit more from undergoing percutaneous coronary intervention (PCI) than receiving medical therapy alone for blocked coronary arteries, according to late-breaking clinical trial results presented at the American Heart Association’s Scientific Sessions 2007.

November 4, 2007 – The antiplatelet drug prasugrel offered greater benefit than current, standard therapy for patients who have undergone percutaneous coronary intervention (PCI), according to a late-breaking clinical trial presented at the American Heart Association’s Scientific Sessions 2007.

Dual antiplatelet therapy with aspirin plus a prescription antiplatelet drug is standard treatment for helping reduce complications such as heart attacks or clotting in stents in patients with acute coronary syndromes (ACS) who have undergone PCI to open blocked coronary arteries.

November 4, 2007 - A small, implantable device that helps the heart pump blood works equally well for men and women but may benefit twice as many women awaiting transplants, researchers reported at the American Heart Association’s Scientific Sessions 2007.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now